The good, the bad and the ugly
review
OA: bronze
CC0
AI-generated summary
This paper analyzes the current market landscape for ovulation induction drugs by framing the competitive dynamics between key players as a narrative of alliances against a dominant force.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
After recently spending 2 days listening to a group of very distinguished professors and scientists with many years of experience in ovulation induction, and having read the recent debate on Puregon Just as in the original movie, the good guy and the ugly guy join forces to fight the bad guy in their quest for the hidden gold (the market, in our movie).
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Efficacy of treatment for unexplained infertility 1998
- A prospective randomized trial of artificial insemination versus intercourse in cycles stimulated with human menopausal gonadotropin or clomiphene citrate 1993
- Menotropins alone are superior to a clomiphene citrate and menotropin combination for superovulation induction among clomiphene citrate failures 1996
- Future use of clomiphene in ovarian stimulation. Will clomiphene persist in the 21st century? 1998
References (8)
- A prospective randomized trial of artificial insemination versus intercourse in cycles stimulated with human menopausal gonadotropin or clomiphene citrate via openalex
- Efficacy of treatment for unexplained infertility via openalex
- Future use of clomiphene in ovarian stimulation. Will clomiphene persist in the 21st century? via openalex
- Menotropins alone are superior to a clomiphene citrate and menotropin combination for superovulation induction among clomiphene citrate failures via openalex
- W4249309457 via openalex
- W1996720970 via openalex
- W2127851996 via openalex
- W2130168345 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK